Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Cytarabine for Transient Myeloproliferative Disorder in Down Syndrome
NCT00411281Phase 3Withdrawn
- Sponsor
- Children's Oncology Group
- Start
- Mar 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of cytarabine in transient myeloproliferative disorder (TMD) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free survival. Planned start Mar 2006; status: withdrawn.
02
Drugs
cytarabine
03
Conditions
transient myeloproliferative disorder (TMD)
Beyond the preview
Go deeper on NCT00411281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411281.